Publications by authors named "Shivani Dalal"

Article Synopsis
  • The study investigates the prevalence of pathogenic germline variants (PGVs) in patients with non-small cell lung cancer (NSCLC), specifically analyzing data from 878 patients in South Florida between 2019 and 2022.
  • The analysis revealed that 2.4% of the patients had incidental PGVs, with a notable 52.4% identifying as Hispanic/Latinx.
  • Most patients with iPGVs also had co-existing somatic alterations, and a significant portion displayed alterations in genes that could be targeted for therapy, highlighting the importance of genetic testing in diverse populations.
View Article and Find Full Text PDF

Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes. Given the sheer heterogeneity of various subtypes and the rarity of the disease, the management of sarcomas has been challenging, with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma.

View Article and Find Full Text PDF

Human epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of four transmembrane glycoproteins with tyrosine kinase activity, all structurally related to epidermal growth factor receptor (EGFR). These tyrosine kinases are involved in the transmission of cellular signals controlling normal cell growth and differentiation. If this transmission goes awry, it can lead to dysregulated growth of the cell.

View Article and Find Full Text PDF

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that are involved in the regulation of cell proliferation, survival, and development. FGFR alterations including amplifications, fusions, rearrangements, and mutations can result in the downstream activation of tyrosine kinases, leading to tumor development. Targeting these FGFR alterations has shown to be effective in treating cholangiocarcinoma, urothelial carcinoma, and myeloid/lymphoid neoplasms, and there are currently four FGFR inhibitors approved by the Food and Drug Administration (FDA).

View Article and Find Full Text PDF

Several cases of myocarditis and pericarditis have been reported after mRNA COVID-19 vaccination. Interestingly, most cases were seen in male adolescents and young adults, commonly after 3-4 days of the second dose of mRNA vaccine. The vaccine contains the viral spike glycoprotein in the nucleoside-modified mRNA of the coronavirus that activates the proinflammatory cascades and immunological pathways, which can cause myocarditis and pericarditis.

View Article and Find Full Text PDF